08:00 , Nov 10, 2014 |  BioCentury  |  Product Development

Following the Blueprint

After completing an annotated library to bootstrap the development of inhibitors of almost any kinase, Blueprint Medicines has disclosed two test-case inhibitors intended to show how the library can tackle tough targets. The company now...
07:00 , Oct 23, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer AT rich interactive domain 1A (ARID1A); ARID1B; breast cancer 1 early onset (BRCA1); BRCA2; K-Ras (KRAS); phosphoinositide 3-kinase (PI3K) Genetic studies identified mutations in...
07:00 , Jun 12, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer AT rich interactive domain 1A (ARID1A); ARID1B Cell culture studies suggest inhibiting ARID1A or ARID1B could sensitize tumors to radiotherapy and chemotherapy. In cultured...
08:00 , Mar 6, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer AT rich interactive domain 1A (ARID1A); ARID1B Cell culture studies suggest inhibiting ARID1B could help treat cancers with ARID1A mutations. ARID1A and B are...
08:00 , Mar 6, 2014 |  BC Innovations  |  Targets & Mechanisms

Depending on SWI/SNF

Gain-of-function alterations in histone-modifying proteins drive multiple cancers and are now being targeted by compounds in the clinic, 1 but loss-of-function mutations, which are more frequently found in chromatin remodelers, remain largely intractable. Separate teams...
07:00 , Jul 25, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Melanoma Mitochondrial oxidative phosphorylation Cell culture and mouse studies suggest inhibiting oxidative phosphorylation could help treat drug-resistant melanoma. In cultured, drug-resistant melanoma cells that highly...
07:00 , Jun 9, 2008 |  BioCentury  |  Emerging Company Profile

Constellation: More epigenetic stars

Researchers have been working in the field of epigenetics for a long time, but so far few targets have been identified. And only two classes of targets - histone deacetylases and DNA methyltransferases - have...